Navigation Links
Parthenon Identifies Emerging Opportunities in Targeted Payload Cancer Therapeutics
Date:9/5/2012

WHITE PLAINS, N.Y., Sept. 5, 2012 /PRNewswire/ -- Parthenon Associates, LLC ("Parthenon" www.parthenonassociates.com), a Financial Consulting firm that provides research and strategic advisory services to Life Sciences, Biotechnology, and Development-Stage Technology companies, has released its report on Targeted Payload Cancer Therapeutics (TPCTs).  The report examines the promise of TPCTs, drugs that combine precision cancer-targeting agents with toxins or radioisotopes, to create powerful and safe treatments for many forms of cancer with a $15 billion market potential.  An in-depth analysis of the dynamic cancer market, cancer treatment, TPCT development, TPCT economic and reimbursement issues, as well as an examination of companies developing these novel drugs are included.

Key Highlights

  • Targeted Payload Cancer Therapeutics recently hit three milestones, rekindling excitement among investors about their marketplace viability, including FDA approval of a TPCT drug and promising results in Phase III trials of two different products. 
  • There is a small but growing pipeline of promising TPCTs in earlier phases of clinical testing.  These products are positioned as first line treatments for indications with significant unmet medical needs.
  • Next generation TPCTs are expected to be priced at a premium based on the cost of alternative treatments, survival benefits, and the economic/reimbursement environment.  Product case studies suggest potential prices ranging from $60,000 to more than $100,000 per treatment.
  • Actinium Pharmaceuticals, Inc. is poised to attain a leadership position in the development TPCTs that combine radioisotope payloads with monoclonal antibody targeting agents.  The company has two lead products already tested in about 300 patients with Phase I and II clinical trials underway:  Iomab-B for preparing difficult-to-treat cancer patients for hematopoietic stem cell transplant and Actimab-A for the treatment of acute myeloid leukemia (AML) in the elderly.
  • Actinium's Alpha Particle Immunotherapy Platform (APIT) uses more powerful, safer radiation than in current TPCT products and has broad applications for the treatment of many cancers.

About the authors
The 100+ page report was compiled over several months by a team with extensive and varied experience in healthcare.  Key members are:

  • Robert LeBoyer, Founder of Parthenon Associates, is a veteran Healthcare Equity Research Analyst.
  • Philip Cohen is an Industry Consultant and Science Journalist with 20 years of expertise covering medicine and biotechnology.

About our services
Parthenon Associates provides research and strategic advisory services to companies in the Life Sciences, Biotechnology, and Development-Stage Technology industries.  Parthenon's Corporate Services include advising companies on product development acquisitions and product licensing, investor relations, and capital markets issues.

Media Contact:
Robert LeBoyer, Principal. T: (914) 594-4931.  media@parthenonreports.com.


'/>"/>
SOURCE Parthenon Associates, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. In Vitro Diagnostics (IVD) - Emerging Countries (Brazil, Russia, India, China) Opportunity Assessment, Competitive Landscape and Market Forecasts to 2018
2. QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio
3. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
4. Synthetic Biology: Emerging Global Markets
5. Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response
6. All Market Research New Report @ The Worldwide Industry & Regional Market Opportunities With Forecasts to 2016 for Amplifiers and Integrated Microwave Assemblies. (Code name: AIMAs)
7. Its Indiana State Fair Season: New BioCrossroads Report Emphasizes Opportunities in Food and Agriculture Innovation
8. Medtech Expands Nursing Education Opportunities In Florida
9. 2012 US Coagulation Market Outlook: Growth Opportunities and Strategies
10. Healthcare Cloud Computing (Clinical, EMR, SaaS, Private, Public, Hybrid) Market - Global Trends, Challenges, Opportunities & Forecasts (2012 - 2017)
11. Access BridgeGap Ventures to Focus on Early-Stage Therapeutic Opportunities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... ... of the North American Spine Society (NASS)1 demonstrate high fusion rates at ... cases, when PEEK-OPTIMA™ HA Enhanced is used for interbody-fusion devices. The implantable ...
(Date:1/17/2017)... MILPITAS, Calif. , Jan. 17, 2017 /PRNewswire/ ... today announced that it has initiated a global ... PTG-100, an oral peptide that targets alpha4beta7 integrin. ... design study is to evaluate the safety/tolerability and ... colitis patients with moderate to severe active disease. ...
(Date:1/16/2017)... -- Eurofins Genomics today announced the expansion of its Express ... their primers in a shorter turnaround time, without the ... other providers. Express oligos are available for anyone in ... additional fee. Researchers use the oligos for ... genotyping, site-directed mutagenesis, and cloning. Often, they are custom ...
(Date:1/13/2017)... , ... January 13, 2017 , ... ... products containing an organic compound called fulvic acid that farms, greenhouses and hydroponics ... that grow cannabis are among the fastest growing segments of customers using this ...
Breaking Biology Technology:
(Date:1/6/2017)... 2017  SomaLogic announced today that it has ... by iCarbonX, the China -based ... Digital Health Ecosystem that can define each person,s ... biological, behavioral and psychological data, the Internet and ... SomaLogic will provide proteomics data and applications expertise ...
(Date:1/4/2017)... 2017  CES 2017 – Valencell , the ... announced the launch of two new versions of ... biometric sensor modules that incorporate the best of ... expertise. The two new designs include Benchmark BE2.0, ... and Benchmark BW2.0, a 2-LED version of its ...
(Date:12/22/2016)... SuperCom (NASDAQ:   SPCB ... e-Government, Public Safety, HealthCare, and Finance sectors announced today that Leaders ... to implement and deploy a community-based supportive services program to reduce ... , further expanding its presence in the state. ... This new program, which is expected ...
Breaking Biology News(10 mins):